Stapokibart improves quality of life, including sleep, in patients with chronic rhinosinusitis with nasal polyps
In a post hoc analysis of the phase 3 CROWNS-2 study, stapokibart significantly improved SNOT-22 domain scores for nasal, ear/facial, sleep, and emotion compared to placebo during the 24-week double-blind period. These improvements were maintained or further improved during the open-label extension and safety follow-up periods, indicating sustained clinical benefit.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Stapokibart improves quality of life, including sleep, in patients with chronic rhinosinusitis with nasal polyps The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Stapokibart improves quality of life, including sleep, in patients with chronic rhinosinusitis with nasal polyps
This conclusion is most relevant to: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the phase 3 CROWNS-2 study.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]. (Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026) —
How It Works
The proposed biological pathway:
- ▸Stapokibart binds to IL-4 receptor α subunit
- ▸Blocks IL-4 and IL-13 signaling pathways
- ▸Reduces type 2 inflammation in nasal and sinus mucosa
- ▸Improves sinonasal symptoms and quality of life domains including sleep
Who Might Benefit
Evidence fit by population:
- ▸Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the phase 3 CROWNS-2 study
Recommended Dose
300 mg every 2 weeks
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Post hoc analysis, not pre-specified primary endpoint
- ▸Abstract does not report effect sizes or statistical details for sleep domain specifically
Frequently Asked Questions
What is stapokibart?▼
Stapokibart is an anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody that blocks IL-4 and IL-13 signaling pathways, used to treat chronic rhinosinusitis with nasal polyps.
How does stapokibart improve sleep in CRSwNP patients?▼
By reducing nasal congestion, rhinorrhea, and facial pain/pressure, stapokibart alleviates symptoms that interfere with sleep, as measured by the SNOT-22 sleep domain.
What is the SNOT-22?▼
The 22-item sinonasal outcome test is a validated questionnaire assessing quality of life in sinonasal conditions, covering domains such as nasal symptoms, ear/facial symptoms, sleep, and emotion.
Is this study based on a randomized controlled trial?▼
Yes, the CROWNS-2 study is a phase 3 randomized controlled trial, but this analysis is a post hoc analysis of that trial.
References
- 1.Yan B, Jin Z, Zhang L, Wang C. “[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]..” Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026. PMID: 42402685 DOI: 10.13201/j.issn.2096-7993.2026.07.010